Dyne Therapeutics Inc’s recent filing unveils that its Chief Medical Officer Farwell Wildon unloaded Company’s shares for reported $26347.0 on Mar 12 ’24. In the deal valued at $25.58 per share,1,030 shares were sold. As a result of this transaction, Farwell Wildon now holds 150,560 shares worth roughly $3.93 million.
Then, Brumm Joshua T sold 66,387 shares, generating $1,704,142 in total proceeds. Upon selling the shares at $25.67, the CEO & President now owns 537,998 shares.
Before that, McNeill Jonathan sold 19,601 shares. Dyne Therapeutics Inc shares valued at $499,842 were divested by the Chief Business Officer at a price of $25.50 per share. As a result of the transaction, McNeill Jonathan now holds 139,408 shares, worth roughly $3.64 million.
Morgan Stanley initiated its Dyne Therapeutics Inc [DYN] rating to an Overweight in a research note published on April 30, 2024; the price target was $40. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in mid February with a ‘”a Buy”‘ rating. Raymond James also remained covering DYN and has increased its forecast on February 27, 2023 with a “Strong buy” recommendation from previously “an Outperform” rating. Oppenheimer started covering the stock on February 15, 2023. It rated DYN as “an Outperform”.
Price Performance Review of DYN
On Friday, Dyne Therapeutics Inc [NASDAQ:DYN] saw its stock jump 0.31% to $26.08. Over the last five days, the stock has gained 5.46%. Dyne Therapeutics Inc shares have risen nearly 96.09% since the year began. Nevertheless, the stocks have risen 116.07% over the past one year. While a 52-week high of $30.27 was reached on 03/01/24, a 52-week low of $6.40 was recorded on 01/03/24. SMA at 50 days reached $26.30, while 200 days put it at $15.92. A total of 0.76 million shares were traded, compared to the trading of 0.94 million shares in the previous session.
Levels Of Support And Resistance For DYN Stock
The 24-hour chart illustrates a support level at 25.53, which if violated will result in even more drops to 24.98. On the upside, there is a resistance level at 26.97. A further resistance level may holdings at 27.86. The Relative Strength Index (RSI) on the 14-day chart is 52.63, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.02, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 29.29%. Stochastics %K at 67.18% indicates the stock is a holding.
The most recent change occurred on January 26, 2023 when Guggenheim began covering the stock and recommended ‘”a Buy”‘ rating along with a $33 price target.
